|
The Technology Commercialization team launched its first industry-specific version of our “Becoming an Investor-Ready Entrepreneur” program (IRE). The workshop focused on raising equity capital for pharmaceutical development. The strategies for raising funds in this industry are unique and drove the need to roll out this new version.
We are seeing record levels of investment in pharma companies in part by the pandemic but, also, the strong investor returns driven by the current biopharma exit landscape. Investors are investing at earlier stages with in-vivo proof of concept data being a major trigger for pre-IND venture capital investments. During the program, our expert panelists discussed topics related to what investors expect before making investments and how they approach concepts like valuation, deal structure, and ROI. We also discussed strategies for finding and engaging investors.
One pharma company attendee noted: “This event will prepare you not only for financing your company but also strategically positioning your R&D for commercial success.”
A big thanks goes to our panelists:
- Ben Scruggs, Ph.D., Hatteras Venture Partners
- Bert Kinsey, Ph.D., Pappas Capital
- Bill Wofford, J.D., Hutchison PLLC
- Katie Warner, Ph.D., Ribometrix
- Michael Dial, Ph.D., Hatteras Venture Partners
- Vivian Doelling, Ph.D., North Carolina Biotechnology Center
If you’re an early-stage pharma company, don’t hesitate to reach out to Mike Carnes (mcarnes@sbtdc.org) to discuss your company’s funding needs and how key learnings from the workshop might apply to your business.
| 
